Unexpected consequences arise from our incomplete knowledge of the immune system. Who, for example, would have predicted that natalizumab, a monoclonal antibody targeting α4 integrin on leukocytes, would dramatically increase the risk of developing progressive multifocal leukoencephalopathy without
No takes yet. Share an insight, caveat, or question.
Bourdette et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: